The health-economic implications of the "Irbesartan in Diabetic Nephropathy Trial" (IDNT) in France and Belgium

被引：1
|
作者：
Palmer, AJ
Annemans, L
Roze, S
Lamotte, M
Guilhaume, C
Gabriel, S
Carita, P
Chen, R
Simon, T
Rodby, R
Cordonnier, DJ
机构：
[1] CHU Grenoble, F-38043 Grenoble, France
[2] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Sanofi Synthelabo, Bagneux, France
[5] State Univ Ghent, HEDM, Meise, Belgium
[6] CORE Ctr Outcomes Res, Basel, Switzerland
来源：
VALUE IN HEALTH | 2002年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61441-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：546 / 546
页数：1
相关论文
共 50 条
  • [31] Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
    Heerspink, Hiddo J. Lambers
    Weldegiorgis, Misghina
    Inker, Lesley A.
    Gansevoort, Ron
    Parving, Hans-Henrik
    Dwyer, Jamie P.
    Mondal, Hasi
    Coresh, Josef
    Greene, Tom
    Levey, Andrew S.
    de Zeeuw, Dick
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (02) : 244 - 250
  • [32] A prospective study of total homocysteine and pooled cardiovascular disease outcomes in the Irbesartan Type 2 Diabetic Nephropathy Trial Cohort.
    Bostom, A
    Friedman, A
    Hunsicker, L
    Jacques, P
    Selhub, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 672A - 672A
  • [33] The Association of Vitamin D Deficiency and Insufficiency with Diabetic Nephropathy: Implications for Health Disparities
    Diaz, Vanessa A.
    Mainous, Arch G., III
    Carek, Peter J.
    Wessell, Andrea M.
    Everett, Charles J.
    [J]. JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2009, 22 (05) : 521 - 527
  • [34] IS THERE A THRESHOLD IN FRANCE?: FIRST EXHAUSTIVE REVIEW OF PUBLISHED HEALTH-ECONOMIC APPRAISALS BY THE HAUTE AUTORITE DE SANTE (HAS), (FRENCH NATIONAL AUTHORITY FOR HEALTH)
    Cartier-Bechu, C.
    Gherardi, A.
    Sivignon, M.
    Pignata, M.
    Petitjean, A.
    Monnier, R.
    Roze, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A490 - A490
  • [35] Health-related quality of life (HRQOL) and health-economic assessment in patients with von Willebrand disease in France: the WISH-QOL study
    Borel-Derlon, A.
    Goudemand, J.
    Boyer-Neumann, C.
    Fressinaud, E.
    Ternisien, C.
    Trossaert, M.
    Veyradier, A.
    Martinez, C.
    Chatelanaz, C.
    Von Mackensen, S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 739 - 739
  • [36] Towards sustainable mental health promotion: trial-based health-economic evaluation of a positive psychology intervention versus usual care
    Schotanus-Dijkstra, Marijke
    Drossaert, Constance H. C.
    Pieterse, Marcel E.
    Walburg, Jan A.
    Bohlmeijer, Ernst T.
    Smit, Filip
    [J]. BMC PSYCHIATRY, 2018, 18
  • [37] Towards sustainable mental health promotion: trial-based health-economic evaluation of a positive psychology intervention versus usual care
    Marijke Schotanus-Dijkstra
    Constance H. C. Drossaert
    Marcel E. Pieterse
    Jan A. Walburg
    Ernst T. Bohlmeijer
    Filip Smit
    [J]. BMC Psychiatry, 18
  • [38] A prospective study of C-Reactive Protein and pooled cardiovascular disease outcomes in the irbesartan type 2 diabetic nephropathy trial cohort.
    Bostom, A
    Friedman, A
    Hunsicker, L
    Jacques, P
    Selhub, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 672A - 672A
  • [39] Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies
    Garuoliene, Kristina
    Godman, Brian
    Gulbinovic, Jolanta
    Schiffers, Krijn
    Wettermark, Bjorn
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 149 - 152
  • [40] An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France
    Souchet, T
    Zaleski, ID
    Hannedouche, T
    Rodier, M
    Gaugris, S
    Passa, P
    [J]. DIABETES & METABOLISM, 2003, 29 (01) : 29 - 35
12345